Acumen Pharmaceuticals to Present ALTITUDE-AD Trial Data at CTAD
Acumen Pharmaceuticals says it will present preliminary baseline characteristics and data on care experiences and participation from its Phase 2 ALTITUDE-AD trial at the CTAD conference.